MarketCapExport financials
Sage Therapeutics (SAGE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sage Therapeutics Income Statement 2024-2011 | SAGE
Brief overview of profit and loss at Sage Therapeutics
This overview is based on financial performance over the past five years. According to figures from Sage Therapeutics, revenue changed from $6.9 million to $41.2 million over five years. The five-year change reached +500.5%, while CAGR stood at 43.1%. This pace points to rapid expansion of the business.
Over the period, EBITDA shifted from −$706 million to −$431 million, a change of +38.9%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin moved from −10277.2% to −1045.8%. A wider margin confirms stronger operating efficiency.
The net financial result changed from −$680 million to −$401 million. The loss narrowed, although sustainable profitability has not yet returned.
Market capitalization changed from 3.4 billion dollars to 434 million dollars (−87.2%). Financial performance is stronger than the share-price trend.
Summary assessment
The results present an uneven picture without one dominant signal. Key strengths include a larger revenue base, improving net profitability and an improving EBITDA margin. The most visible risks are a weaker market valuation and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Sage Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
434 M | 1.54 B | 2.65 B | 2.5 B | 4.5 B | 3.4 B | 6.12 B | 7.04 B | 1.54 B | 933 M | 871 M | - | - | - |
Shares |
60.8 M | 59.8 M | 59.3 M | 58.7 M | 52 M | 50.8 M | 46.1 M | 38.1 M | 33.5 M | 27.8 M | 21.6 M | - | - | - |
Historical Prices |
7.15 | 25.7 | 44.7 | 42.5 | 86.5 | 72.2 | 95.8 | 165 | 51.1 | 58.3 | 36.6 | - | - | - |
Net Income |
-401 M | -541 M | -533 M | -458 M | 606 M | -680 M | -373 M | -270 M | -159 M | -94.5 M | -33.8 M | -18.3 M | -9.63 M | - |
Revenue |
41.2 M | 86.5 M | 7.69 M | 6.31 M | 1.11 B | 6.87 M | 90.3 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 6.47 M | - | - | - | - | - | - | - | - |
Operating Income |
-432 M | -580 M | -547 M | -461 M | 596 M | -708 M | -393 M | -273 M | -160 M | -94.6 M | -33.8 M | -18.3 M | -9.63 M | - |
Interest Expense |
29 K | -383 K | 15 K | 134 K | 250 K | 82 K | 22 K | -64 K | -35 K | -23 K | -9 K | -3 K | -1 K | - |
EBITDA |
-431 M | -578 M | -546 M | -457 M | 599 M | -706 M | -392 M | -273 M | -160 M | -94.5 M | -33.8 M | -18.2 M | -9.59 M | - |
Operating Expenses |
474 M | 666 M | 555 M | 467 M | 518 M | 715 M | 484 M | 273 M | 160 M | 94.6 M | 33.8 M | - | - | - |
General and Administrative Expenses |
216 M | 275 M | 228 M | 183 M | 197 M | 346 M | 157 M | 51.7 M | 34.1 M | 22.2 M | 9.71 M | 3.38 M | 2.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Sage Therapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
62.6 M | 61.9 M | 61.4 M | 61.1 M | 60.5 M | 60.1 M | 60 M | 59.9 M | 59.8 M | 59.7 M | 59.5 M | 59.4 M | 59.3 M | 59 M | 58.9 M | 58.8 M | 58.6 M | 58.4 M | 58.3 M | 52 M | 51.9 M | 51.9 M | 51.9 M | 51.7 M | 51.3 M | 48.5 M | 46.9 M | 46.7 M | 46.5 M | 44.3 M | 42 M | 37.5 M | 37.4 M | 37.3 M | 37.2 M | 33 M | 32.1 M | 31.6 M | 28.8 M | 28.7 M | 27.9 M | 25.7 M | 25.6 M | 19.6 M | 1.7 M | 1.65 M | 1.62 M | 1.51 M | 1.46 M | - | - | - | - | - | - | - | - | - |
Net Income |
-49.7 M | -62.2 M | - | -93.6 M | -103 M | -108 M | - | -202 M | -160 M | -147 M | - | -137 M | -126 M | -122 M | - | -130 M | -107 M | -95.8 M | 975 M | -106 M | -136 M | -127 M | -169 M | -180 M | -168 M | -163 M | -158 M | -123 M | -17 M | -74.6 M | -69.4 M | -73.7 M | -70.2 M | -56.8 M | -55.9 M | -37.8 M | -34.7 M | -30.5 M | -28.6 M | -24 M | -25 M | -16.9 M | -12.4 M | -9.47 M | -6.19 M | -5.79 M | - | -4.52 M | -4.66 M | - | - | - | - | - | - | - | - | - |
Revenue |
31.7 M | 14.1 M | - | 11.9 M | 8.65 M | 7.9 M | - | 2.72 M | 2.47 M | 3.29 M | - | 1.74 M | 1.5 M | 1.58 M | - | 1.44 M | 1.64 M | 1.58 M | 1.11 B | 1.64 M | 1.09 M | 2.29 M | 1.96 M | 3.57 M | 873 K | 465 K | 273 K | 90 M | 90 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-54 M | -67.5 M | - | -101 M | -111 M | -118 M | - | -212 M | -170 M | -155 M | - | -141 M | -128 M | -123 M | - | -131 M | -108 M | -96.5 M | 974 M | -107 M | -139 M | -132 M | -175 M | -187 M | -176 M | -170 M | -164 M | -129 M | -22.1 M | -78.1 M | -70.4 M | -74.4 M | -70.9 M | -57.5 M | -56.4 M | -38.1 M | -35 M | -30.7 M | -28.6 M | -24.1 M | -25.1 M | -16.9 M | -12.4 M | -9.47 M | -6.19 M | -5.79 M | - | -4.52 M | -4.66 M | - | - | - | - | - | - | - | - | - |
Interest Expense |
-6 K | 18 K | - | 9 K | 15 K | -12 K | - | -55 K | -41 K | -188 K | - | 30 K | 45 K | -24 K | - | 31 K | 44 K | 35 K | - | 76 K | -66 K | 155 K | - | -8 K | 16 K | 4 K | - | 10 K | 32 K | -8 K | - | -23 K | -20 K | -5 K | - | -7 K | -7 K | -4 K | - | -6 K | -9 K | 5 K | - | -1 K | -5 K | - | - | 1 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-53.8 M | -67.3 M | - | - | - | -117 M | - | - | - | -155 M | - | -141 M | -128 M | -123 M | - | -127 M | -107 M | -93.9 M | 974 M | -106 M | -138 M | -131 M | -175 M | -186 M | -176 M | -169 M | -164 M | -128 M | -21.9 M | -77.9 M | -70.4 M | -74.3 M | -70.8 M | -57.2 M | -56.4 M | -37.9 M | -34.9 M | -30.7 M | -28.6 M | -24 M | -25 M | -16.9 M | -12.4 M | -9.44 M | -6.17 M | -5.78 M | - | -4.48 M | -4.63 M | - | - | - | - | - | - | - | - | - |
Operating Expenses |
85.6 M | 81.5 M | - | 113 M | 120 M | 126 M | - | 215 M | 173 M | 159 M | - | 143 M | 130 M | 125 M | - | 132 M | 110 M | 98.1 M | 135 M | 109 M | 140 M | 134 M | 177 M | 191 M | 177 M | 170 M | 164 M | 129 M | 112 M | 78.1 M | 70.4 M | 74.4 M | 70.9 M | 57.5 M | 56.4 M | 38.1 M | 35 M | 30.7 M | 28.6 M | 24.1 M | 25.1 M | 16.9 M | 12.4 M | 9.47 M | 6.19 M | 5.79 M | - | 4.52 M | 4.66 M | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
62 M | 57.6 M | - | 53.2 M | 56 M | 52.6 M | - | 78.1 M | 75.6 M | 65.7 M | - | 61.5 M | 52.4 M | 46.5 M | - | 48.7 M | 43.3 M | 39.8 M | - | 35.1 M | 38.2 M | 70.1 M | - | 88.5 M | 88.2 M | 83.9 M | - | 53.7 M | 43.2 M | 28.8 M | - | 16.1 M | 15 M | 12.3 M | - | 8.99 M | 8.91 M | 7.13 M | - | 6.6 M | 6.46 M | 4 M | - | 2.87 M | 1.81 M | 1.62 M | - | 1.11 M | 801 K | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Sage Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
$ 291.22 | 1.06 % | $ 515 B |  USA |
 |
22nd Century Group
XXII
|
$ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
$ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
$ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
- | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
$ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
$ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
$ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
$ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
$ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
$ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
- | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
$ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
$ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
- | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
$ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
- | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
$ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
$ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
- | - | $ 521 M | USA |
 |
Codexis
CDXS
|
$ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
$ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
$ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
- | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
$ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
- | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
$ 0.88 | 3.67 % | $ 11.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
- | - | - |  Russia |
 |
CorMedix
CRMD
|
$ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
$ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
CRISPR Therapeutics AG
CRSP
|
$ 50.09 | 3.15 % | $ 4.5 B | Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
$ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
$ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
- | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
- | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
$ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
- | -55.98 % | $ 2.15 M | USA |